SONIO
20.12.2022 09:31:44 CET | Business Wire | Press release
Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.
Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.
“Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”
“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.
Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:
- Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
- Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.
Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).
“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.
About Sonio
Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.
Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.
Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 17:09:00 CEST | Press release
Approximately 130 Cessna, Beechcraft and Hawker aircraft and volunteer pilots mobilize to transport more than 800 Special Olympics athletes and coaches to the 2026 Special Olympics USA Games The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 16:53:00 CEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
